Lefamulin acetate (Xenleta)

Lefamulin acetate (Xenleta) (CAS No.: 1350636-82-6) is a semisynthetic pleuromutilin class antibacterial research compound, derived from the pleuromutilin natural product scaffold of microbial origin and broadly categorized as a protein synthesis inhibitor for anti infective pharmacology and translational microbiology studies; mechanistically, it acts through selective engagement of the peptidyl transferase center within the 50S bacterial ribosomal subunit, thereby disrupting transfer RNA positioning and peptide bond formation and ultimately suppressing bacterial protein biosynthesis, with additional reports of inflammation modulating activity that support investigation in host pathogen interaction systems; across susceptible bacterial panels in preclinical literature, activity is commonly reported in the low micromolar to sub micromolar range depending on strain background and assay configuration, while detailed potency metrics may vary with medium composition, inoculum size, and resistance determinants; in biomedical research and drug discovery workflows, this agent is frequently used to profile ribosome targeted antibacterial mechanisms, evaluate cross resistance against other translation inhibitors, benchmark structure activity relationships within pleuromutilin analog series, and support efficacy oriented studies in cell based infection models and in vivo bacterial burden models, where the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.